Pro-Dex, Inc.
HealthcareNASDAQ:PDEX · NASDAQ Capital Market
-$0.72 today
Vol 0.10M · Avg 0.03M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
24.5%
avg 18.0%
ROIC
15.0%
avg 10.9%
ROA
14.7%
avg 11.9%
Analysis
ROE is currently the strongest return metric at 24.5% versus its period average of 18.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard Lee Van Kirk Jr. | Chief Executive Officer, President, Chief Operating Officer & Director | $605,321.00 | — | 65 | $91,011.00 | 2.85% |
Alisha K. Charlton | Chief Financial Officer & Corporate Secretary | $310,195.00 | — | 56 | $16,267.00 | 0.51% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
6
$626,247.68
Net Sentiment
$626,247.68
Net selling
Most Active
Van Kirk Richard Lee Jr
6 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 6 sells worth $626,247.68 over the last 12 months. That adds up to net selling of $626,247.68. Van Kirk Richard Lee Jr was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -8.1% | +16.2% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.1% over three years. Forward estimates point to Revenue at +16.2% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$353.16M
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Microbot Medical Inc.
NASDAQ:MBOT
$81.12M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
Sera Prognostics, Inc.
NASDAQ:SERA
$71.42M
SkyAI, Inc.
STSS
$47.61M
Incannex Healthcare Limited
IXHL
$43.99M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Who manages PDEX?
Pro-Dex, Inc. (PDEX) lists 2 active executives. The top listed executive is Alisha K. Charlton, Chief Financial Officer & Corporate Secretary.
Are PDEX insiders buying or selling?
Recent insider activity shows net buying of $710,509.05.
Explore More
Continue the stock analysis
Jump to another research area for this company.